Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
申请人:Kwok Lily
公开号:US09073918B2
公开(公告)日:2015-07-07
The present invention provides ALK5 inhibitors of the formula
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.
PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5
申请人:Kwok Lily
公开号:US20130324528A1
公开(公告)日:2013-12-05
The present invention provides ALK5 inhibitors of the formula
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.
POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR
申请人:Hangzhou Innogate Pharma Co., Ltd.
公开号:EP3686196A1
公开(公告)日:2020-07-29
The present invention provides polycyclic compounds as IDO inhibitors and/or dual inhibitors of IDO-HDAC. Specifically, the present invention provides compounds represented by the following formula (I), wherein each group is defined as described in the specification. The compounds have IDO inhibitory activity or IDO-HDAC dual inhibitory activity and can be used for preventing or treating diseases associated with IDO and/or IDO-HDAC activity or expression levels. At the same time, the compounds of the present invention can be combined with an antitumor antibody such as PD-1 and PD-L1, and such a combination can greatly increase the antitumor response rate of the antibody and broaden the types of tumors to be treated.